Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.N Engl J Med. 2015; 373: 737-746
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Lancet. 2016; 387: 1163-1177
- Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2019; 17: 479-505
- Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.N Engl J Med. 2017; 377: 352-360
- Abiraterone for prostate cancer not previously treated with hormone therapy.N Engl J Med. 2017; 377: 338-351
- Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial.J Clin Oncol. 2018; 36: 1080-1087
- ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.J Clin Oncol. 2019; 37: 2974-2986
- Apalutamide for metastatic, castration-sensitive prostate cancer.N Engl J Med. 2019; 381: 13-24
- Enzalutamide with standard first-line therapy in metastatic prostate cancer.N Engl J Med. 2019; 381: 121-131
- Breast cancer screening and diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2018; 16: 1362-1389
- Combining endocrine agents with chemotherapy: which patients and what sequence?.Cancer. 2008; 112: 718-722
- Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer.Eur J Cancer. 2016; 69: 216-222
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.Lancet. 2018; 392: 2353-2366
J.J.A. and J.P.R. contributed equally to this work as first authors.